Clin2
NCT06977308Possibly a fitNot yet recruiting

Brain imaging study of dopamine in early psychosis risk

Clinical High Risk for Psychosis (CHR)

Treatments studied

Part of Mental health clinical trials.

This study uses brain scans and a medication called methylphenidate (Ritalin) to understand how the brain chemical dopamine works in people at early risk for psychosis. It may help researchers find better ways to predict and treat psychosis.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
115 people
Ages
18 years to 30 years
Study type
Interventional

Who can take part

  • You are 18 to 30 years old.
  • You have been identified as at Clinical High Risk for psychosis.
  • You have NOT taken antipsychotic medication in the past 3 weeks, or you have never taken it.
  • You do not have a current substance abuse problem (other than nicotine or caffeine) in the last month.
  • You are not a daily smoker.
  • You are not pregnant, breastfeeding, or have an unstable medical condition.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07226895Recruiting· Phase 1/Phase 2
Study of MT1988 for people at high risk for psychosis

This trial tests a new drug called MT1988 in people who show early warning signs of psychosis. Researchers want to see if it changes certain markers in the body related to mental health.

Irvine, California
NCT07434973Not yet recruiting· Phase 3
Early psychosis prevention with cannabidiol (CBD)

This trial tests if cannabidiol (a non-psychoactive cannabis component) can prevent psychosis in people ages 12-35 at high risk. It compares CBD to a placebo to see if it reduces symptoms and delays or prevents a first psychotic episode.

Vienna
NCT06542640Recruiting
Understanding brain changes in youth at risk for psychosis

This research study looks at how the brain changes in young people who are at high risk for developing psychosis. It aims to find better ways to predict and prevent psychosis by using brain imaging and thinking tests.

Shanghai, Shanghai Municipality
NCT07715253Not yet recruiting· Phase 1
Brain imaging study of antipsychotics in schizophrenia

This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.

NCT07483294Recruiting· Phase 4
Brain imaging study for first-episode psychosis treatment

This study uses brain scans to find markers that can predict how well antipsychotic medications work in people having their first episode of psychosis. It aims to help doctors choose the right treatment earlier.

Glen Oaks, New York
NCT05011760Recruiting· Early Phase 1
PET brain scan with a cocaine-use disorder medicine test

This early-phase study uses a PET brain scan (a special imaging test) to see how the brain responds in people with cocaine use disorder. It aims to better understand brain activity and whether this scan approach could help research or future treatments.

Pittsburgh, Pennsylvania

Hear when a new Clinical High Risk for Psychosis (CHR) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.